D. King

[99mTc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial

K. Pitman, D. Chepeha, N. Hall, 2015, Annals of Surgical Oncology.

Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

V. Sondak, J. Messina, S. Leong, 2012, Annals of Surgical Oncology.

Comparative Evaluation of [Tc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials

Linda K. Han, C. Hoh, H. Krontiras, 2013 .

The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care

A. Wallace, D. Vera, F. Cope, 2012, Clinical & Experimental Metastasis.

Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials

Linda K. Han, C. Hoh, H. Krontiras, 2013, Annals of Surgical Oncology.

The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care

A. Wallace, D. Vera, F. Cope, 2012, Clinical & Experimental Metastasis.

The novel receptor targeted (CD206) 99mTc-labeled tilmanocept versus the currently employed Tc99m-sulfur colloid in intraoperative lymphatic mapping (ILM) on key performance metrics breast cancer.

F. Cope, D. King, Lori A. Christman, 2012 .